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Objectives: The localized delivery of exogenous, angiogenic growth factors such as fibroblast growth factor (FGF)-2 has
become a promising alternative treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI). The present
study describes the efficacy of fragmin/protamine microparticles containing FGF-2 (F/P-MPs/FGF-2) to promote
vessel growth in a rabbit model of hindlimb ischemia.
Methods: A total of 24 rabbits were used to construct a model of hindlimb ischemia by resection of the left femoral artery. The
rabbits were randomly divided into four groups 10 days after surgery (day 0); group A: control (non-treated; 1 mL of
phosphate-buffered saline [PBS]); group B: FGF-2 (100 g FGF-2 in 1 mL PBS)-treated; group C: F/P-MPs (12 mg dried
F/P MPs in 1 mL PBS)-treated; and group D; F/P MPs/FGF-2 (100 g FGF-2 and 12 mg dried F/P MPs in 1 mL
PBS)-treated (n 6 each). The drugs were administered intramuscularly to each group. Blood flow and blood pressure were
measured in each group on days 0, 14, and 28. Angiography was performed to assess arteriogenesis on day 28. The number
of capillaries on day 28 was determined by direct counting CD31 and -smooth muscle antibody (-SMA)-positive vessels.
Results: Neither death nor wound infection was observed throughout the experiment. The F/P MPs/FGF-2-treated
group showed marked improvement in the blood flow ratio, blood pressure ratio, and capillary number in comparison to
the control group, FGF-2-treated group, and F/PMPs-treated group. The F/PMPs-treated group showed intermediate
improvement in blood flow ratio and capillary number in comparison to the control group and FGF-2-treated group.
Conclusions: The F/P MPs/FGF-2-treated group strongly induced functional collateral vessels in the rabbit model of
hindlimb ischemia, indicating a possible therapy for PAD. (J Vasc Surg 2011;54:791-8.)
Clinical Relevance. PAD due to atherosclerotic vascular disease is a major health problem. Despite recent advances in
surgical and radiologic vascular techniques, certain patients with CLI are not suitable for revascularization. A variety of
strategies have been tried to promote development of collateral vessels. F/P MPs can act as carriers for controlled release
of FGF-2. The purpose of this study was to evaluate the efficacy of F/PMPs/FGF-2 to induce functional collateral vessels
in a rabbit model of hindlimb ischemia. This study will lead to F/PMPs/FGF-2-therapy which is an effective therapeutic
strategy for treating PAD patients in clinic.
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oPeripheral arterial disease (PAD) is a common cause of
disability and morbidity.1 Despite recent advances in surgical
and radiologic vascular techniques, certain patients with criti-
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doi:10.1016/j.jvs.2011.02.060al limb ischemia (CLI) are not eligible for those revascular-
zation procedures, because of the anatomical location of the
esions, the extent of the disease, or extensive comorbidity,2,3
nd no pharmacologic therapy has been established.4
Amputation, despite its associated morbidity, mortality
ates, and functional implications, is occasionally recom-
ended as a solution to the disabling symptoms, especially
or those patients with CLI experiencing excruciating isch-
mic pain.5 A variety of other strategies have also been tried
or the creation of collateral vessels as an alternative ap-
roach to the management of severe ischemia, with the
ope of preventing amputation from nonreconstructable
ascular diseases.6 Those strategies included uses of numer-
us angiogenic factors, including fibroblast growth factor
FGF)-2, vascular endothelial growth factor (VEGF), and
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September 2011792 Horio et alhepatocyte growth factor (HGF), which are known to
promote collateral vessel formation in animal models of
limb and myocardial ischemia.7,8 In addition, introduc-
tions of bone marrow cells or adipose-derived stromal cells
and direct injection of naked plasmid DNA encoding hu-
man VEGF or recombinant growth factors have a potential
to induce angiogenesis.1,9 Although some of those studies
have revealed good results, their performance is limited by
high cost.7,9
Two forms of vessel growth “angiogenesis and arterio-
genesis” are observed after birth.10,11 Angiogenesis is de-
fined as the formation of new capillaries by sprouting and
arteriogenesis as the growth of collateral arteries. Arterio-
genesis refers to the maturation and stabilization process of
preexisting arterioles, which includes smooth muscle cell
(SMC) recruitment and vessel enlargement through vascu-
lar remodeling.6 Arteriogenesis increases blood flow 10- to
20-fold, whereas angiogenesis increases 1.5- to 1.7-fold.11
Therefore, the growth factor used for therapy should po-
tently induce arteriogenesis to develop large-conductance
collateral vessels.
FGF-2 is one of the most suitable growth factors for
angiogenic therapy that can induce more mature vessels
and promote more collateral vessel development.7,8 The
difficulty with the use of FGF-2 is the low accumulation in
the ischemic tissue and rapid inactivation. In addition,
FGF-2 itself has an acute vasodilatory effect12 and the
potential to induce nephropathy in a dose-related man-
ner.13 Therefore, studies have investigated carriers for con-
trolled release of FGF-2. Recently collagen,14 gelatin,15-17
fibrin,18 and alginate19 have been evaluated as carriers for
controlled release of FGF-2. Two clinical trials in Japan
have evaluated the use of gelatin hydrogel as a control
releasing carrier for FGF-2.20,21 One study used 100 g of
FGF-220 and the other used 200 g.21 Application of the
appropriate carrier for controlled release enabled dose re-
duction and vessel growth at target site. These trials showed
a certain level of efficacy, but there were some patients who
showed allergy symptoms to gelatin hydrogel.22
Fragmin/protamine microparticles (F/P MPs) have
been evaluated as carriers for controlled release of FGF-2.8
Low-molecular-weight heparin (fragmin) mixed with
protamine formed water-insoluble microparticles (about
0.5-3 m in diameter), and F/P MPs containing FGF-2
(F/P MPs/FGF-2) induced temporal vascularization and
fibrous tissue formations in normal mice.8 Cytokines, ex-
tracellular matrix components, adhesion molecules, and
heparin could be useful therapeutic agents for various
pathologic conditions in which such functional proteins are
involved, because heparin and fragmin interact with a vari-
ety of functional proteins such as growth factors.22-24
However, high-dose heparin cannot be used because of the
excessive risk of bleeding.25 In contrast, fragmin has phar-
macologic and practical advantages in comparison to hep-
arin. Fragmin induces a low, stable, and predictable antico-
agulant response, obviating the need for laboratory
monitoring to adjust dosage. In addition, one or two
subcutaneous injections per day are sufficient to maintain sherapeutic concentrations in blood because of the longer
lasma half-life of fragmin.26,27 We previously reported
hat fragmin has minor prolonged activated partial throm-
oplastin time and prothrombin time, compared with na-
ive heparin,8 and injection of fragmin and F/P MPs never
aused bleeding at injection sites.
On the other hand, protamine, a purified mixture of
roteins obtained from fish sperm, neutralizes heparin by
orming a stable complex that lacks anticoagulant activ-
ty.28 Protamine is also in clinical use as an antidote to
eparin to reverse its anticoagulant activity following car-
iopulmonary bypass and in cases of heparin-induced
leeding.28 Fragmin without bleeding potency and prota-
ine was used to prepare F/P MPs as an FGF-2-carrier for
romotion of vessel growth in a rabbit model of hindlimb
schemia. F/PMPs used in this study were about 1 to 3 m
n diameter with a degradation time of 2 weeks.8 This
eport describes the efficacy of F/P MPs/FGF-2 to induce
unctional collateral vessels in a rabbit model of hindlimb
schemia in comparison to F/P MPs and FGF-2 alone.
ETHODS
Preparation of F/P MPs.8 It is well-known that the
ixing of anionic and cationic macromolecules in solution
eads to the formation of colloidal anionic molecules/
hitosan aggregation complexes (polyelectrolyte com-
lexes [PECs]). Protamine solution (0.6 mL) (10 mg/mL;
ochida Pharmaceutical, Tokyo, Japan) was added drop-
ise to 1.4 mL of fragmin solution (6.4 mg/mL; Kissei
harmaceutical, Tokyo, Japan) with vigorous mixing using
ortex Genie-2 mixer (Scientific Industries, Inc, Bohemia,
Y) for approximately 2 minutes to produce the colloidal
ECs. Protamine and fragmin were mixed in a ratio at 3:7
vol: vol) to maximize the productions ofMPs in this study.
he solution of F/P MPs (2 mL) was then washed twice
ith phosphate-buffered saline (PBS) to remove unreacted
omponents, and then the volume was increased to 1 mL
ith PBS. About 12 mg of the dry F/P MPs was obtained
rom 2 mL of the F/PMPs solution. The F/PMPs used in
his study were about 0.5 to 3 m in diameter, and the F/P
Ps (200 L) subcutaneously injected into mice visually
isappeared within 2 weeks.8,9
Animal model of hindlimb ischemia. The present
tudy used a rabbit model of hindlimb ischemia in all
xperiments. Male New Zealand White rabbits weighing
.0 to 3.5 kg (Kitayama Rabes Co, Ltd, Nagano, Japan)
ere anesthetized with an intramuscular injection of a
ixture of 50 mg/kg ketamine (Daiichi-Sankyo Co, Ltd,
okyo, Japan) and 5 mg/kg xylazine (Bayer Ltd, Tokyo,
apan). The hindlimb ischemia model was created by re-
ecting the left femoral artery from the inguinal ligament to
he popliteal fossa and bifurcation of the saphenous artery.
he deep femoral artery was preserved (Fig 1). The rabbits
ere then maintained for 10 days on a normal diet to avoid
ild inflammation occurred by the surgery in the mod-
ls.29,30 All animal experiments were performed under
terile conditions and in accordance with the guidelines of
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Volume 54, Number 3 Horio et al 793the Institutional Animal Care and Use Committee of Na-
tional Defense Medical College (Tokorozawa, Japan).
Study protocol. Rabbits were randomly divided into
four groups 10 days after surgery (day 0). Group A: control
(non-treated: 1 mL phosphate-buffered saline [PBS])
group; group B: FGF-2 (100 g FGF-2 in 1 mL PBS)-
treated group; group C and F/P MPs (12 mg dried F/P
MPs in 1 mL PBS)-treated group; and group D and F/P
MPs/FGF-2 (100 g FGF-2 and 12 mg dried F/PMPs in
1 mL PBS)-treated group (n  6 each). Rabbits in groups
A, B, C, andDwere administered the drugs intramuscularly
into two different sites in the adductor muscle and three
different sites in the semimembranous muscle of ischemic
hindlimb with a 27 G needle and a 1 mL syringe (0.2 mL
each into five separate injections). Collateral vessel devel-
opment was evaluated by blood flow, blood pressure, an-
giography, and pathologic analyses. Calf blood flow ratios
and blood pressure ratios were determined 10 days after the
creation hindlimb ischemia (day 0), day 14, and day 28.
Angiograms were taken on day 28.
Laser Doppler perfusion imaging. Hindlimb perfu-
sion was assessed using laser Doppler perfusion imaging
(LDPI) (LSFG; Advance Co, Ltd, Tokyo, Japan) on days 0,
14, and 28. LDPI provides a noninvasive measurement of
blood flow by determining the Doppler frequency shift due
to light reflecting off the moving red blood cells. The
Doppler perfusion in the limb was measured from the
thigh, including femoral adductors to knee. Color images
were obtained and blood flow ratio was determined as the
ratio of perfusion of the ischemic left hindlimb to that of the
intact right hindlimb.
Measurement of calf blood pressure. Calf blood
pressure was measured on days 0, 14, and 28, using non-
invasive blood pressure monitor (SurgiVet V6004; Smiths
Medical PM, Inc, Waukesha, Wisc) and 25-mm-wide cuff.
In brief, both hindlimbs were shaved and cleaned on the
day before measurement. The rabbits were anesthetized,
Fig 1. The rabbit acute hindlimb ischemia model was created by
resecting the left femoral artery from the inguinal ligament to the
popliteal fossa and bifurcation of the saphenous artery.and a 25-mm-wide cuff was wrapped around the calf along uhe course of the posterior tibial artery to determine the
ystolic, diastolic, andmean blood pressures. The calf blood
ressure ratio (L/R ratio) was determined as the ratio of
ystolic pressure of the ischemic left hindlimb to that of the
ntact right hindlimb.
Angiography and quantification of collateral growth.
ngiography was performed to visualize collaterals (200
m in diameter) on day 28 just before killing. The jugular
ein was cannulated for continuous infusion of lactated
inger’s solution and occasional injections of pentobarbital
o maintain an appropriate level of anesthesia. A 5F intro-
ucing sheath (Medikit, Tokyo, Japan) was inserted into
he right common carotid artery. Rentogenographic imag-
ng (Series 9800; A GE Medical Systems, Inc, Salt Lake,
tah) was used to guide the sheath into the descending
orta. A 3F catheter was placed in a proximal position in the
ommon iliac artery. The manufacturer revealed that the
ngiography system has resolution capacity of200 m in
iameter. Ten milliliters of contrast medium (320 mg
odine/mL; Omnipaque, Amersham, Nydalen, Norway)
ere manually injected at the rate of 2 mL/s. Serial images
ere recorded at the rate of 8 images per second for 6
econds, and the image representing the best arterial filling
as chosen for analysis. The resulting angiograms were
ssessed in a single-blinded fashion under stereoscopic
iewing for quantification of the visible collateral arteries.
nly vessels unquestionably showing a defined stem-,
id-, and re-entrant zone according to the Longland clas-
ification31 were counted and marked to confirm that no
essel was counted twice.
Histology and capillary vessel measurements. Open
horacotomy was performed after angiography on day 28,
nd the inferior vena cava was dissected and cannulated
ith a 16-gauge (G) catheter. Rabbits were heparinized
ith 2000 IU heparin, and sacrificed with overdose injec-
ions of pentobarbital (Dainippon Sumitomo Pharma, To-
yo, Japan). The organs were fixed by perfusion with 10%
eutral-buffered formaldehyde at 120 cm H2O (88.2 mm
g) through the abdominal aorta. Excessive blood was left
ut through the vena cava. Semimembranous muscles of
he ischemic limb were excised and immersed another 24
ours in 10% neutral-buffered formaldehyde, and embed-
ed in paraffin and cut into 4-m transverse tissue sections.
he tissues were stained by hematoxylin-eosin and Mas-
on’s trichrome for pathologic assessment. Immunohisto-
hemical staining was carried out with a monoclonal anti-
ody against human CD31 (JC/70A; Dako, Carpinteria,
alif) to detect vascular endothelial cells. Those sections
ere also immunostained for -SM actin (H0708; Nichirei
ioscience Corporation, Tokyo, Japan) to detect vascular
mooth muscle cells. The capillary number represents total
essels counted from 10 different fields randomly selected
t 200 magnification in a blinded manner attained by
D31 and -SM actin double-immunostaining superim-
osed upon the same field images stained with Masson’s
richrome reagent.
Statistical analyses. Statistical analyses were performed
sing the State Mate Version III software package (Win-
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September 2011794 Horio et aldows version; ATOMS, Tokyo, Japan). Statistical signifi-
cance was evaluated by one-way analysis of variance
(ANOVA), followed by Dunn-test as post hoc test. Values
are presented as the mean SD. P values less than .05 were
considered statistically significant.
RESULTS
Laser Doppler perfusion imaging. Thus, F/P MPs/
FGF-2 has no side effects in at least rabbits. Calf blood flow
ratios were determined 10 days after hindlimb ischemia
creation (day 0). There were no significant differences
observed among four groups. The blood flow ratio showed
significant improvement in the F/P MPs/FGF-2-treated
group in comparison to the control, FGF-2-treated, and
F/P MPs-treated groups on days 14 and 28. On the other
hand, the blood flow ratio in the F/P MPs-treated group
also showed significant improvement in comparison to the
control group and FGF-2-treated groups on days 14 and
28 (Fig 2). The values of blood flow (intact limbs) were
81.3  14.9. The hindlimb blood flow determined imme-
diately prior to surgery was identical to the value of the
intact limb.
Measurement of calf blood pressure. The calf blood
pressure in the ischemic limbs was below the level of
detection (30 mm Hg) in all four groups before the initia-
tion of therapy (day 0). However, the calf blood pressure
ratio on days 14 and 28 showed significant improvement in
the F/P MPs/FGF-2-treated group in comparison to the
control, FGF-2-treated, and F/P MPs-treated groups (Fig
3) while there were no significant differences among the
control, FGF-2-treated, and F/P MPs-treated groups. On
the other hand, the values of blood pressure (intact limb)
were 105.6 13.7, and the calf blood pressure determined
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Fig 2. Laser Doppler perfusion imaging. No significant differ-
ences in blood flow ratio of the control (white bar), FGF-2-treated
(light gray bar), F/P MPs-treated (dark gray bar), and F/P MPs/
FGF-2-treated (black bar) groups were observed on day 0. The
blood flow ratio showed significant improvement in the F/P
MPs-treated and F/PMPs/FGF-2-treated groups on days 14 and
28. Data represent themean SD of six determinations. *P .05.immediately prior to surgery was identical to the value. MAngiography and quantification of collateral growth.
ig 4 show angiograms of the rabbits on day 28. Quan-
ification of visible collateral arteries has been performed
ith the radiographic appearances under stereoscopic view-
ng. The number of angiographically visible collateral arter-
es in the control group, FGF-2-treated, F/P MPs-treated,
nd F/PMPs/FGF-2-treated groups were 7 1, 7 1, 11
, and 16  2, respectively (Fig 5). Therefore, significant
ncreases of detectable collateral arteries were observed in
he F/P MPs/FGF-2- and F/P MPs-treated groups and
hose in the F/P MPs/FGF-2-treated groups were signif-
cantly higher than that in F/P MPs-treated groups (P 
001).
Histology and capillary vessel measurements. F/P
Ps/FGF-2-treatment induced marked improvement on
he number of mature capillaries in comparison to the
ontrol, FGF-2-, and F/P MPs-treatments on day 28 (Fig
). The F/P MPs/FGF-2-treated group showed mature
nlarged vessels (200 m in diameter) with thick medial
ayers containing SMCs. On the contrary, the control- and
GF-2-treatments did not induce such enlarged vessels,
nd the F/P MPs-treatment induced large vessels poorly.
urthermore, those in the F/P MPs-treated group pos-
essed only thin medial layers containing SMCs. Therefore,
he enlarged vessels with a medial layer containing SMCs in
he F/PMPs/FGF-2-treated and F/PMPs-treated groups
ppeared to reflect the improvement of blood flow (Fig 6).
The number of histologically visible capillaries (50
m in diameter) counted from 10 different fields randomly
elected at 200 magnification in a blinded manner at-
ained by CD31 and -SM actin double-immunostaining
uperimposed upon the same field images stained with
asson’s trichrome reagent in the FGF-2-treated, F/P
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Volume 54, Number 3 Horio et al 7951, 8  1, 15  1, and 23  2, respectively (Fig 7). The
number of enlarged vessels (200 m in diameter) that
possessed a medial layer containing SMCs among those
capillary in the control group, FGF-2-treated, F/P MPs-
treated, and F/P MPs/FGF-2-treated groups were 0, 0,
4  1, and 8  1, respectively.
DISCUSSION
The principal goal of angiogenic therapy is to develop
collateral vessels that can provide sufficient blood flow to
the pre-existing vascular network in ischemic tissue.31
Newly formed capillaries lack a medial layer containing
SMCs and, therefore, have little effect on total vascular
resistance. In contrast, arteriogenesis involves the growth,
development, and remodeling of pre-existing vessels
(mainly arterioles) into larger collateral arteries of sufficient
diameter (200 m in diameter) to be visualized by an-
giography that can serve as conduit arteries and influence
Fig 4. Angiograms of ischemic limb on day 28.A, control group.
B, FGF-2-treated group. C, F/P MPs-treated group. D, F/P
MPs/FGF-2-treated group. The top angiogram shows a represen-
tative for intact limb. Photographs are representative of six angio-
grams in each of four groups.vascular resistance.32,33 Results obtained in this study dem- pnstrated clearly that the F/P MPs/FGF-2-treatment
ould stimulate arteriogenesis as well as angiogenesis at a
arget site in a rabbit model of hindlimb ischemia in com-
arison to the control-, FGF-2-, and F/P MPs-treated
roups.
The methods used for the evaluation of calf blood
ressure, hindlimb perfusion, angiography, and histology
erformed in this study have been used frequently to assess
ollateral vessel development.15,32,33 Although CD-31-
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Ps/FGF-2-treated group. Each photograph is a representative of
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SMC-positive vessels are considered to be parameters of
arteriogenesis. Both the hemodynamics and histology in
the current study demonstrated that F/P MPs/FGF-2-
treatment induced remarkable improvement of blood flow
and pressure. The histology demonstrated dilated blood
vessels in conjunction with medial hypertrophy, and nu-
merous inflammatory cells, possibly macrophages, were
observed in the medial layer only in the F/P MPs/FGF-2-
treated group. FGF-2 may play an important role to induce
SMCs and macrophages migration as a mediator since
SMCs and macrophages are activated by numerous cyto-
kines and growth factors such as MCP-1, TNF-, FGF-2,
and matrix metalloproteinases involved in arteriogenesis,6
which act as mediators via autocrine or paracrine mecha-
nisms. Those results suggested that the F/P MPs/FGF-2-
treatment could stimulate arteriogenesis as well as angio-
genesis at a target site in a rabbit model of hindlimb
ischemia.
F/P MPs-treatment also showed significant improve-
ments in blood flow ratio and capillary number in compar-
ison to the control- and FGF-2-treated groups on day 28
but those efficacies were lower than that of F/P MP/
FGF-2. We previously showed that various growth factors
in platelet-rich plasma (PRP) effectively bind to F/P MPs,
and F/P MPs maintain and enhance their biological activ-
ities in vitro and in vivo.34 The result suggested that the
activities of various endogenous angiogenic growth factors
produced at the wound areas accompanied by inflamma-
tion may be enhanced with their bindings to F/P MPs and
in turn F/P MPs allow their stabilization, local accumula-
tion, and controlled release due to high affinity of F/PMPs
for the matrix. Similarly, F/P MPs may bind various en-
dogenous (heparin-binding) angiogenic growth factors ac-
companied by the removal of the femoral artery and may
allow their local accumulation and controlled release.
The most widely studied techniques have been local
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Fig 7. The number of capillaries was counted from 10 different
fields randomly selected at 200 magnification in a blinded man-
ner determined by CD31 and -SM actin double-immunostaining
superimposed upon the same field images stained with Masson’s
trichrome reagent. Data represent the mean  SD of six determi-
nations. *P  .05, **P  .01.delivery of angiogenic growth factors such as VEGF, and aany researchers have confirmed that exogenous angio-
enic growth factors can induce the formation of new
lood vessels and increase collateral blood flow in ischemic
issues.35-37 However, although VEGFs markedly induce
ngiogenesis, administration of large doses causes edema
nd induces the development of functionally abnormal
lood vessels. In contrast, FGF-2 leads to the formation of
ranulation tissue, and thereafter, induction of microves-
els. Furthermore, FGF-2 can enhance SMC recruitment
hich leads to arteriogenesis. However, one difficulty in
he use of FGF-2 lies in its low accumulation in the ischemic
issues and its rapid inactivation.38 Therefore, application
f the appropriate carrier for controlled release enables dose
eduction and vessel growth at target site, since the activity
f FGF-2 is stabilized and enhanced,8,34 and since F/P
Ps/FGF-2 rapidly binds to various cell surfaces and ex-
racellular matrix components,9 F/P MPs may allow their
tabilization, local accumulation, and controlled release.
It has been also reported that introductions of bone
arrow cells or adipose-derived stromal cells have a poten-
ial to induce angiogenesis.1,9 In addition, clinical studies
ave revealed good results following direct injection of
aked plasmid DNA encoding human VEGF or recombi-
ant growth factors. However, their performance is limited
y high cost.7,9
F/P MPs have a high affinity for FGF-2 molecules and
rotect FGF-2 from heat and proteolytic inactivation and
nhance the FGF-2-activity.8 In addition, FGF-2 is gradu-
lly released from F/P MPs/FGF-2 (6 mg/mL F/P MPs
nd 50 g/mL FGF-2, injection of 100 L in each site),
nd local delivery of the F/P MPs/FGF-2 leads to induc-
ion of local angiogenesis and fibrous tissue formation in
ormal mice.8 However, the previous study did not evalu-
te the induction of arteriogenesis. In this study, we tested
everal different dosages for this rabbit hindlimb ischemia
odel, and we adopted the optimum dosage of F/PMPs/
GF-2 (12 mg/mL F/P MPs and 100 g/mL FGF-2,
njection of 200 L in each site) for injections. Although
he efficacy of F/P MPs/FGF-2 for arteriogenesis was
aintained rabbit model of hindlimb ischemia for at least 6
eeks, we speculate that maintenance of a collateral bed
equired repeated injections of FGF-2 every 2 months or
onger. Neither death, wound infection, nor any morbidity
as observed using the optimal dosage of F/P MPs/
GF-2 throughout the experiment.
No bleeding complications were observed in the ani-
als injected with F/P MPs in the previous study.8,9
lthough all components for F/PMPs (fragmin and prota-
ine) are in clinical use and FGF-2 was already used in
linical trial, their safety needs further evaluation.8,9 In
ddition, the F/P MPs/FGF-2 can be made quickly and
asily by simply mixing the three components at the time of
se. This study clearly demonstrated that F/PMPs/FGF-2
an stimulate local arteriogenesis as well as angiogenesis in
rabbit model of hindlimb ischemia. Therefore, F/PMPs/
GF-2 may be a promising new biomaterial to induce
rteriogenesis as well as angiogenesis in ischemic limbs.
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The current study evaluated the ability of F/P MPs/
FGF-2 to induce both arteriogenesis and angiogenesis in
ischemic limbs. The primary conclusion is that F/P MPs/
FGF-2-treatment effectively induces the development of
collateral vessels, which can provide sufficient blood flow to
the pre-existing vascular network in ischemic tissue. Thus,
F/P MPs may be a promising effective carrier for FGF-2-
therapy for PADpatients. However, since sufficient data are
not yet available on the complete toxicity profile of the F/P
MPs/FGF-2, standard toxicologic studies need to be com-
pleted prior to using the F/P MPs/FGF-2 in human
subjects.
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